Kashiwabara et al. [56] analyzed the efficacy of EGFR-TKI in combination with talcum powder in patients with MPE and lung adenocarcinoma, 34 of whom received TKI as first-line therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.